Fiduciary Trust Co Sells 316 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Fiduciary Trust Co decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 3.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 8,206 shares of the biopharmaceutical company’s stock after selling 316 shares during the period. Fiduciary Trust Co’s holdings in Regeneron Pharmaceuticals were worth $5,846,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in REGN. Capital International Investors grew its stake in shares of Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company’s stock worth $3,373,859,000 after acquiring an additional 1,390,534 shares during the period. Geode Capital Management LLC grew its holdings in Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company’s stock valued at $1,726,940,000 after purchasing an additional 155,369 shares during the period. Dodge & Cox increased its holdings in Regeneron Pharmaceuticals by 0.4% in the 4th quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company’s stock worth $1,653,543,000 after acquiring an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company’s stock worth $1,485,527,000 after purchasing an additional 810,144 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Regeneron Pharmaceuticals by 7.9% during the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company’s stock valued at $1,456,864,000 after acquiring an additional 149,124 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on REGN shares. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $750.00 to $700.00 and set an “overweight” rating for the company in a research note on Wednesday, April 30th. Leerink Partners raised Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and upped their target price for the company from $762.00 to $834.00 in a research note on Wednesday, February 5th. BMO Capital Markets decreased their price objective on shares of Regeneron Pharmaceuticals from $865.00 to $800.00 and set an “outperform” rating for the company in a report on Wednesday, April 30th. Guggenheim dropped their price target on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a “buy” rating on the stock in a research report on Thursday, May 1st. Finally, Canaccord Genuity Group raised shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, April 22nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $892.60.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $527.78 on Friday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a 12-month low of $520.50 and a 12-month high of $1,211.20. The firm’s fifty day moving average price is $613.08 and its 200 day moving average price is $696.77. The company has a market capitalization of $57.70 billion, a price-to-earnings ratio of 13.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.43.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts’ consensus estimates of $8.83 by ($0.61). The business had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $9.55 EPS. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be given a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.67%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.